Adama joined Eradigm in August 2022 as an Associate Consultant, bringing to the team extensive experience in market access and clinical care.
In her previous role, Adama worked on developing pricing, reimbursement, and market access strategies for clients in the pharmaceutical and biotechnology industries in the UK, EU, and US, with a focus on rare diseases and orphan drugs. She was involved in consulting projects helping clients understand pricing and revenue potential by building tools accounting for country-specific Health Technology Assessment and reimbursement systems, client and competitor strategy, and launch sequencing. Adama also gained experience developing payer value propositions and objection handlers.
Adama has an MSc in Drug Discovery and Pharma Management from University College London (UCL), through which she gained an understanding of both the regulatory and commercial aspects involved in drug development. Her master’s thesis explored the feasibility of CAR-T therapy development and manufacturing for Pharma in the context of rising decentralisation by means of increasing Hospital Exemption use. Adama also holds a BSc Pharmacology and Therapeutics with a minor in Economics from McGill University and a BPharm from the University of Manitoba in Canada, where she gained deep scientific and clinical care knowledge of medicines.
Outside of work, Adama can usually be found in or adjacent to a bakery. She also enjoys playing football to keep fit, as well as watching anime, going to art exhibitions, and eating good food (to keep unfit).